Australian researchers have found a new treatment for prostate cancer that could help millions of men around the world.
The drug overcomes the twin problems that have plagued researchers for decades — stopping both the spread of tumours and drug resistance.
Developed by Griffith University researcher Professor Des Richardson and colleagues from The University of Sydney, the drug known as “DpC” both directly inhibits the compounds causing prostate cancer and stops their receptors from working.
Professor Richardson said the current “gold standard” for prostate cancer treatment also leads to drug resistance, so can eventually become ineffective.
“This finding was totally unexpected and very exciting, as for the first time we may be able to treat patients using a new therapy that is miles ahead of the current standard anti-cancer chemotherapy for prostate cancer, Enzalutamide”.
In cancer, intricate networks of signalling pathways interact with each other to control the growth of a tumour.
Professor Richardson says DpC “unexpectedly” overcomes this cancer signalling by the testosterone hormone.
It’s not the first unique anti-cancer compound developed by Professor Richardson, who has spent the past 25 years researching drugs that have been tested for the treatment of a wide range of highly resistant and difficult-to-treat tumours.
Support our universities as they make life-saving breakthroughs – sign the petition to #KeepItClever now.